Protocolo diagnóstico de las miocardiopatías

  1. García Campos, A. 1
  2. Pérez Domínguez, M. 1
  3. Díaz Fernández, B. 1
  4. González Juanetey, J.R. 1
  1. 1 Servicio de Cardiología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, La Coruña, España, CIBERCV
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2021

Issue Title: Enfermedades cardiovasculares (VIII)

Series: 13

Issue: 42

Pages: 2486-2489

Type: Article

DOI: 10.1016/J.MED.2021.09.025 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

Cardiomyopathies are a heterogeneous group of diseases that are classified based on their morphological phenotype. According to this phenotype, a detailed personal and family medical history are crucial in determining whether the disease is of familial origin or not. The information obtained through imaging and laboratory tests will complement the etiological diagnosis of the cardiomyopathies. Genetic tests may be indicated with the aim of refining the diagnosis and prognosis and guiding the family study, but they must be interpreted by professionals trained in their use.

Bibliographic References

  • Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: A scientific statement from the American Heart Association. Circulation. 2016;134(23):e579-e646.
  • Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P. Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2007;29(2):270-6.
  • Hershberger RE, Givertz MM, Ho CY, Judge DP, Kantor PF, Mc-Bride KL. Genetic evaluation of cardiomyopathy : A Heart Failure Society of America Practice Guideline. J Car Fail. 2018; 24(5):281-302.
  • Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal JM, Androulakis AF. Long term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. J Am Coll Cardiol. 2016;68(21):2299-307.
  • Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of nonischaemic cardiomyopathies. Eur Heart J. 2005;26(15):1461-74.
  • Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142(25):e558-e631.
  • Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37(23):1850-8.
  • Rapezzi C, Arbustini E, Caforio ALP, Charron P, Gimeno-Blanes J, Heliö T. Diagnostic work up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(19):1448-58.
  • Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circula-tion. 2003;107(17):2227-32.
  • Roger VL. Epidemiology of heart failure. Circ Res. 2013;113(6):646-59.
  • Seferovic PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(5):553-76.
  • Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH. 2013 ACCF/AHA Guideline for the management of heart failure. J Am Coll Cardiol. 2013;62(16):e147-e239.
Data source: Dialnet